BCL6 Modulation of Acute Lymphoblastic Leukemia Response to Chemotherapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Mar 26

PMID 27015556

Citations 10

Authors

William L Slone

Blake S Moses

Ian Hare

Rebecca Evans

Debbie Piktel

Laura F Gibson

Affiliations

Soon will be listed here.

Abstract

The bone marrow niche has a significant impact on acute lymphoblastic leukemia (ALL) cell phenotype. Of clinical relevance is the frequency with which quiescent leukemic cells, in this niche, survive treatment and contribute to relapse. This study suggests that marrow microenvironment regulation of BCL6 in ALL is one factor that may be involved in the transition between proliferative and quiescent states of ALL cells. Utilizing ALL cell lines, and primary patient tumor cells we observed that tumor cell BCL6 protein abundance is decreased in the presence of primary human bone marrow stromal cells (BMSC) and osteoblasts (HOB). Chemical inhibition, or shRNA knockdown, of BCL6 in ALL cells resulted in diminished ALL proliferation. As many chemotherapy regimens require tumor cell proliferation for optimal efficacy, we investigated the consequences of constitutive BCL6 expression in leukemic cells during co-culture with BMSC or HOB. Forced chronic expression of BCL6 during co-culture with BMSC or HOB sensitized the tumor to chemotherapy induced cell death. Combination treatment of caffeine, which increases BCL6 expression in ALL cells, with chemotherapy extended the event free survival of mice. These data suggest that BCL6 is one factor, modulated by microenvironment derived cues that may contribute to regulation of ALL therapeutic response.

Citing Articles

How CBX proteins regulate normal and leukemic blood cells.

de Groot A, de Haan G FEBS Lett. 2024; 598(22):2788-2806.

PMID: 38426219 PMC: 11586599. DOI: 10.1002/1873-3468.14839.

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.

McLachlan T, Matthews W, Jackson E, Staudt D, Douglas A, Findlay I Mol Cancer Res. 2022; 20(12):1711-1723.

PMID: 36166198 PMC: 9716245. DOI: 10.1158/1541-7786.MCR-22-0567.

Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia.

Piktel D, Nair R, Rellick S, Geldenhuys W, Martin K, Craig M Cancers (Basel). 2022; 14(11).

PMID: 35681662 PMC: 9179467. DOI: 10.3390/cancers14112681.

The Bone Marrow Microenvironment in B-Cell Development and Malignancy.

Hughes A, Kuek V, Kotecha R, Cheung L Cancers (Basel). 2022; 14(9).

PMID: 35565219 PMC: 9102980. DOI: 10.3390/cancers14092089.

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.

Kawabata K, Zong H, Meydan C, Wyman S, Wouters B, Sugita M Blood. 2020; 137(6):812-825.

PMID: 32911532 PMC: 7885821. DOI: 10.1182/blood.2019001745.

References

Wang D, Long J, Dai F, Liang M, Feng X, Lin X . BCL6 represses Smad signaling in transforming growth factor-beta resistance. Cancer Res. 2008; 68(3):783-9. DOI: 10.1158/0008-5472.CAN-07-0008. View

van den Berg H, Desai Z, Wilson R, Kennedy G, Bridges J, Shanks R . The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol. 1982; 8(2):215-9. DOI: 10.1007/BF00255487. View

Chang C, Ye B, Chaganti R, Dalla-Favera R . BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A. 1996; 93(14):6947-52. PMC: 38914. DOI: 10.1073/pnas.93.14.6947. View

Duy C, Yu J, Nahar R, Swaminathan S, Kweon S, Polo J . BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010; 207(6):1209-21. PMC: 2882829. DOI: 10.1084/jem.20091299. View

Baron B, Anastasi J, Montag A, Huo D, Baron R, Karrison T . The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004; 101(39):14198-203. PMC: 521136. DOI: 10.1073/pnas.0406138101. View

Chow D, Wenning L, Miller W, Papoutsakis E . Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J. 2001; 81(2):685-96. PMC: 1301545. DOI: 10.1016/S0006-3495(01)75733-5. View

Moses B, Slone W, Thomas P, Evans R, Piktel D, Angel P . Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype. Exp Hematol. 2015; 44(1):50-9.e1-2. PMC: 4684957. DOI: 10.1016/j.exphem.2015.09.003. View

Bertolo C, Roa S, Sagardoy A, Mena-Varas M, Robles E, Martinez-Ferrandis J . LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. Br J Haematol. 2013; 162(5):621-30. PMC: 4111142. DOI: 10.1111/bjh.12440. View

Duan C, Shi J, Chen J, Wang B, Yu Y, Qin X . Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell. 2014; 25(6):778-93. DOI: 10.1016/j.ccr.2014.04.015. View

10.

Bhojwani D, Sabin N, Pei D, Yang J, Khan R, Panetta J . Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):949-59. PMC: 3948096. DOI: 10.1200/JCO.2013.53.0808. View

11.

Hathcock K . Depletion of accessory cells by adherence to Sephadex G-10. Curr Protoc Immunol. 2008; Chapter 3:Unit 3.6. DOI: 10.1002/0471142735.im0306s08. View

12.

Cerchietti L, Hatzi K, Caldas-Lopes E, Yang S, Figueroa M, Morin R . BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010; 120(12):4569-82. PMC: 2993589. DOI: 10.1172/JCI42869. View

13.

Coustan-Smith E, Sancho J, Hancock M, Boyett J, Behm F, Raimondi S . Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96(8):2691-6. View

14.

Bai M, Agnantis N, Skyrlas A, Tsanou E, Kamina S, Galani V . Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol. 2003; 16(5):471-80. DOI: 10.1097/01.MP.0000067684.78221.6E. View

15.

Samuels A, Beesley A, Yadav B, Papa R, Sutton R, Anderson D . A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. Blood Cancer J. 2014; 4:e232. PMC: 4219466. DOI: 10.1038/bcj.2014.52. View

16.

Ci W, Polo J, Cerchietti L, Shaknovich R, Wang L, Yang S . The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009; 113(22):5536-48. PMC: 2689052. DOI: 10.1182/blood-2008-12-193037. View

17.

Phan R, Saito M, Kitagawa Y, Means A, Dalla-Favera R . Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat Immunol. 2007; 8(10):1132-9. DOI: 10.1038/ni1508. View

18.

Joannon P, Oviedo I, Campbell M, Tordecilla J . High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004; 43(1):17-22. DOI: 10.1002/pbc.20032. View

19.

Liedtke M, Dunn T, Dinner S, Coutre S, Berube C, Gotlib J . Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leuk Res. 2014; 38(12):1441-5. DOI: 10.1016/j.leukres.2014.09.018. View

20.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S . BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011; 473(7347):384-8. PMC: 3597744. DOI: 10.1038/nature09883. View